Morphogenesis, Inc. Signs Agreement to further the Development of Cancer Immunotherapy for Companion Animals
Morphogenesis Inc. and Novartis Animal Health have agreed to collaborate on the development and commercialization of one of Morphogenesis' platform technologies, an investigational immunotherapy treatment for cancers. The objective of this co-development plan will be to produce several canine and feline therapeutic cancer vaccines. Through this agreement, Morphogenesis and Novartis will work closely together to advance the new platform technology to the companion animal market. Morphogenesis is proud to be working with Novartis Animal Health, a company which shares our passion for finding ways to improve the lives of our animal companions. Read the full press release here.
News & Events
Find out more
2203 N Lois Avenue, STE 900, Tampa, FL 33607
Change is the way of life
Morphogenesis inc
Change is the way of life
Events
November 19, 2009
Biotechnology Forum
Dr. Pat Lawman gave seminar on the research and development of Morphogenesis, Inc.
October 16-19, 2009
2009 Annual Veterinary Cancer Society Conference
Dr. Michael Lawman gave an oral presentation on RNA Interference (read abstract) and Dr. Pat Lawman gave an oral presentation on therapeutic canine lymphoma vaccine (read abstract).
September 15, 2009
BioFlorida Southeast Life Science Forum
July 15-16, 2009
World Technology Summit & Awards 2009
May 31, 2008
Theilen Tribute Symposium
March 25, 2008
University of Florida Tech Showcase: A Celebration of Innovation
November 1-4, 2007
Annual Veterinary Cancer Society Conference
October 30, 2007
WilBio's 12th Annual Cell & Tissue BioProcessing Conference
September 11, 2007
BioFlorida Jax
April 14-18, 2007
American Association for Cancer Research Annual Meeting 2007
April 16-20, 2005
American Association for Cancer Research Annual Meeting 2005
In the News
